Sign up for our Oncology Central weekly news round-up

Editor’s highlights from Future Oncology – August 2020

Written by Louis Gautier, Future Science Group

Editor's highlights

In this latest instalment of his regular monthly column, Louis Gautier, Commissioning Editor of Future Oncology, exclusively shares some of his top picks from the recent journal issues, which we have made freely available for you, Oncology Central members! Check out Louis' highlights below: SOLTI-1503 PROMETEO TRIAL: Combination of Talimogene Laherparepvec With Atezolizumab in Early Breast Cancer Talimogene Laherparepvec (T-VEC) is a first-in-class oncolytic immunotherapy based on the herpes simplex virus type 1, which has been most typically investigated in melanomas to date. In this collaborative trial with Roche and Amgen, the SOLTI Breast Cancer Research Group build on previous research...

To view this content, please register now for access

It's completely free